DC-MelVac

a second generation melanoma vaccine (DC-Melvac) that consists of five human melanoma cell lines, a recombinant vaccinia virus that encodes for IL-2, as well as dendritic cells that have been programmed to recognize certain melanoma associated antigens; approved by FDA in Phase I clinical trials 2/2008

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Cancer Vaccines: 4052
      - DC-MelVac: 4

Experts

1.	Alam, Khorshed: 3 articles (05/2007 - 07/2006)
2.	Aydin, Nebil: 3 articles (05/2007 - 07/2006)
3.	Montenegro, Grace: 2 articles (05/2007 - 12/2006)
4.	Wallack, Marc: 2 articles (05/2007 - 07/2006)
5.	Boyes, Christopher: 2 articles (12/2006 - 07/2006)
6.	Jack, Angela: 2 articles (12/2006 - 07/2006)
7.	Degliuomini, J: 1 article (02/2008)
8.	Jack, A: 1 article (02/2008)
9.	Kalani, A D: 1 article (02/2008)
10.	Montenegro, G: 1 article (02/2008)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 02/01/2008 - "The ensuing review discusses many of the immunotherapeutic strategies that have been studied in the treatment of melanoma, including DC-MelVac." 07/01/2006 - "A new second-generation melanoma vaccine, DC-MelVac (patent # 11221/5), has recently been granted FDA approval for Phase I clinical trials and will be introduced in this review." 12/01/2006 - "In the present study, we determined the ability of DCs to express Melanoma-Associated Antigens (MAAs) from a polyvalent Melanoma Vaccine (DC-MelVac; Patent #11221/5) developed in our facility. " 02/01/2008 - "Recently, the same Laboratory has produced a second generation melanoma vaccine (DC-Melvac) that consists of five human melanoma cell lines, a recombinant vaccinia virus that encodes for IL-2, as well as dendritic cells that have been programmed to recognize certain melanoma associated antigens. "
2.	Neoplasms (Cancer) 05/15/2007 - "This vaccine (DC-MelVac; Patent no. 11221/5) has the potential to treat humans with cancer, and has received FDA approval for use in Phase I clinical trials."

Related Drugs and Biologics

1.	Vaccines
2.	Antigens
3.	Interleukin-2 (IL2)